If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
The CEO stated work with the large US biotech partner is progressing well. Down the road any commercial product will lead to meaningful royalties to FAB.
Likewise potential licensing income from collaborating with US Cancer Institute may be company making.
The market cap. Of this cutting edge science outfit would clearly be many, many times greater if listed in the US.
This is a poor reflection on the London stock markets and investing community.
It would be no surprise if FAB is simply snapped up by a foreign listed competitor.
You forget Edinburgh which has a valuable freehold site.
Very positive news for a £2m market cap company. The upside potential is large indeed.
Must be due a trading update soon.
The pharma that moves first will get the rewards.
Nuvec looks like the real deal.
Cash at hand tight?
20,000 followers for Discount Dragons as of today; that is a near 70% growth in just the last three months. Impressive.
Full year financial results for HUD ought to be due in 5/6 weeks, I will be looking for an encouraging update on current trading.
I agree, the number of followers and the growth in the number is a solid indicator of DD popularity, which is clearly growing strongly. My only concern is how profit/loss is going.
If Nuvec could be licensed out to a large Indian pharma company and taken/financed through trials, that would be a sizeable coup for N4p.
I expect we may get an update on Lets Explore and Vodiac soon. Could they be spun off as a separate vehicle? No clues at present, other than the CEO wanting to make sales of these products a year round educational/entertainment business.
Virtual reality products are gaining in popularity, especially after Apple Vision Pro launch. There is a lot of potential in this part of the business.
Discount Dragon continues to perform well it seems. The fulfilment time in order processing is noticeably faster . The product offerings has broadened markedly and quarter over quarter growth in sales will surely look impressive. The question remains re the bottom line and the cost of sales.
Stripping away the sizeable cash position, the stock market valuation looks undemanding for HUD.
N4p received patent award for Nuvec in India, announced not long ago, may have something to do with it.